XTL BIOPHARMACEUTICALS LTD
XTLBNasdaq
$2.89
↑ +1.8%Jul 20 close · end-of-day
Price
1Y↓ -90.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. is headquartered in Ramat Gan, Israel.
- CEO
- Shlomo S. Shalev
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 8
- Website
- xtlbio.com
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.